Mallinckrodt Announces Creation of €10m R&D Facility in Dublin

mallinckrodt, r&d, investment,

Pharmaceutical company Mallinckrodt plc has officially opened its new offices in College Business and Technology Park in Blanchardstown, Dublin.

To accompany the opening the company announced the creation of a new €10 million state-of-the-art Research and Development (R&D) facility at the location. The R&D facility will house global device engineering for the company and bring 40 new jobs to the site, bringing the overall total of new positions to 120 by 2017. Following this this commitment, Mallinckrodt’s total investment in the site has grown to €85m. This project is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.

Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, said: “Today’s dedication and announcement reaffirms Ireland’s strategic importance to Mallinckrodt as we continue with our transition to become a high-growth, global specialty pharmaceutical business. We are in the process of bringing global R&D activities for medical devices to this location and the team will focus on developing systems for delivery of certain specialty pharmaceutical therapies in our portfolio.”

Our Related Content   favourable outlook for Irish retail property, despite Brexit

Mallinckrodt has a long history of operations in Ireland, maintaining a presence in the country for over 20 years. Its new offices at the College Business and Technology Park, Blanchardstown were dedicated this morning by Minister for Social Protection, Leo Varadkar TD, and Mallinckrodt President and Chief Executive Officer, Mark Trudeau.

Commenting, Leo Varadkar, local TD and Minister for Social Protection, said: “I’m delighted to announce this new investment by Mallinckrodt in Blanchardstown. This company is at the cutting edge of new and innovative treatments and the range of facilities being developed here is an exciting development. The Government has worked hard to create the right conditions for cutting edge Pharma and BioPharma companies to locate in Ireland and the provision of high quality jobs in this new Research and Development facility is very welcome. The number of people at work is back up to 2 million and unemployment continues to fall. This investment means more jobs and more quality jobs in our community.”

Our Related Content   1,000 new jobs to be created in Irish space industry

Martin Shanahan, Chief Executive of IDA Ireland, “The Biopharma industry is one of the fastest growing sectors in Ireland. Ireland is a leading location for the manufacture and development of biopharmaceutical medicines in the world. In 2015, the sector employed over 25,000 people in Ireland and has accounted for over €30bn in exports. Biopharma companies like Mallinckrodt are currently developing and manufacturing these “next generation” of medicines from their base here in Dublin. I wish Mark and the Mallinckrodt team every success as they continue to grow their operations in Ireland.”

Pictured above: Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, Leo Varadkar, local TD and Minister for Social Protection, Martin Shanahan, Chief Executive of IDA Ireland and Dr. David Keenan, Vice President, Global External Supply and Managing Director, Mallinckrodt Pharmaceuticals, Ireland